腾博官网诚信为本专业服务

3358288340
CN
CN EN
Kexing Biopharm released the official version of 2020 Annual Report!

Release date:2021 - 04 - 26

In 2020, as Kexing Biopharm overcame the impact of COVID-19 and insisted on stable operation, it achieved a revenue of RMB 1.22 billion, net profit of RMB 139 million and net cash flow of RMB 106 million. Then, it kept enhancing the exploration of sales terminals and promoting fine market channels management. By 2020, Kexing Biopharm's products have been adopted by more than 16,000 sales terminals in China, including more than 6,000 hospitals, and have been registered in, exported and sold to more than 30 countries. Kexing Biopharm has achieved a sustained increase in R&D investment, up 30.20% year-on-year, accelerated the layout of innovative drug projects, and made steady progress in ongoing projects. Finally, it was listed on the Sci-Tech Innovation Board in the A-share market (stock code: 688136), which was deemed as a new historic leap.


20210426103948406


20210426103948810


20210426103948983


20210426103949354


20210426103949483


20210426103950227


20210426103950373


20210426103950846


20210426103950949


20210426103951386


20210426103954244


20210426103954619


20210426103954737


20210426103955171


20210426103957693


20210426103957967


20210426103959609


20210426104647688



















































【网站地图】